-+ 0.00%
-+ 0.00%
-+ 0.00%

BeiGene Switzerland, a subsidiary of BeiGene (688235.SH), plans to subscribe for Bravera Series A financing of 19.5 million US dollars

Zhitongcaijing·11/16/2026 11:41:14
Listen to the news

Zhitong Finance App News, BeiGene (688235.SH) announced that the company's wholly-owned subsidiary BeOne Medicines I GmbH (a company registered in Switzerland, “Baekje Switzerland”) plans to participate with 667, L.P. (“667” for short) and Baker Brothers Life Sciences, L.P. (“Life Sciences”, collectively known as “Baker Bros Entity” with 667) and other investors Series A funding for Bravera Bio, Inc. (“Bravera”). The financing will be completed in three rounds, including one initial delivery and two subsequent deliveries. The two subsequent deliveries will depend on whether the specified milestones and delivery conditions are met or exempted. Baekje Switzerland expects to invest a total of $19.5 million in cash and convert the $500,000 equity interest held under the Simple Future Share Agreement (“SAFE”) into Series A preferred shares of Bravera. After the transaction is completed, Baekje Switzerland will hold 9.477% of Bravera's shares.

The current joint investment between Baekje Switzerland and related parties is based on considerations of the company's overall development strategy and business needs. The source of funding for this transaction is Baekje Switzerland's own funds. The transaction follows the principle of fair trade, and the pricing is fair and reasonable. The transaction will not have a significant adverse impact on the company's main business, ability to operate continuously and asset status, nor will it harm the overall interests of the company and its shareholders.